

LBT RECEIVES \$1.1 MILLION R&D TAX INCENTIVE

Adelaide, Australia, 22 January 2020: LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to advise that it has received a Research & Development (**R&D**) Tax Incentive, net of income tax payable, of \$1.1 Million for the financial year ended 30 June 2019. The amount received is consistent with the Company's previous guidance to the market.

The cash rebate from the Australian Tax Office (ATO) is related to the expenditure on eligible Australian R&D activities conducted during the 2018/2019 financial year.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® Independence is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation. The Company has regulatory cleared analysis modules able to support microbiology laboratories with the automated analysis of urine culture plates and for MRSA infection control.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com